PharmaTelevision - China and Korea - Emerging markets and emerging innovation powerhouses – Stella Xu discusses her department’s role at Roche

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: China and Korea - Emerging markets and emerging innovation powerhouses – Stella Xu discusses her department’s role at Roche

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Dr Stella Xu, Executive Director at Roche Partnering Asia.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Role and responsibilites of Stella Xu at Roche Partnering

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at AusBiotech in Melbourne, October 2010. On this show I have Stella Xu , who is the Executive Director at Roche Partnering, Shanghai Roche Pharmaceuticals Ltd based in Shanghai, China. Welcome to the show.

Stella Xu:

Thank you.

Fintan Walton:

Stella Xu, you play an important role obviously for Roche Partnering you work with Frank Grams, you are based in Shanghai and I understand one of your roles is to go out there and find new innovations, new opportunities. So first of all my first question really is how do you fit in within the Roche? How do you, whom do you reporting to and how do you work with the rest of the Roche Partnering team?

Stella Xu:

Thank you. So I am part of the Global Roche Partnering team, we are based in Shanghai, two-years ago we actually did a strategic project for our executive committee to think about how we can creatively extending our innovation network and one of the topic for discussion was actually emerging markets and the teams recommendations feeling that emerging markets like China, Korea not only are they growing rapidly as a commercial marketplace they are actually emerging innovation powerhouses as well. So look at the scientific publication and looking in the patent application they are all coming up growing rapidly into the innovation landscape for a worldwide perspective, as such we decided to actually relocate two Senior Licensing professional one from Basel, Frank Grams and me from New Jersey to Shanghai, what we do in Shanghai is we are managing the business development activities in Asia outside of Japan. Frank and I we come with complimentary expertise and experience and we work together, we both report into Joe McCracken, who used to be the Business Development Head for Genentech in the last 10 plus years until he moved to Tokyo last October and so Shanghai office work together with Tokyo office and we are managing the business development and innovation collaborative opportunities in Asia.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Stella Xu

Executive Director

Stella Xu is an Executive Director with Roche Partnering Asia Shanghai Roche Pharmaceuticals Ltd . Her major responsibilities include searching potential licensing opportunities (products/technologies), and supporting transaction discussions & alliance management in Asia. Prior to her current position, Stella Xu had held multiple global positions in Roche Partnering in the US and led more than 30 product-focused due diligence projects and alliances, including the latest two major product licensing deals in Asia. Stella Xu joined Roche from McKinsey US, a premier management consulting firm that provides strategic advices to the top management of global business leaders. At McKinsey she led consulting engagements with global biopharmaceutical clients in areas ranging from R&D strategy, marketing & sales, to corporate development and M&A activities. Prior to McKinsey, Stella conducted biotech drug discovery work in oncology and inflammation. Stella Xu received her Ph.D. in Immunology and executive MBA training from Northwestern University, and her B.S. in Biophysics from Peking University.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Shanghai Roche Pharmaceuticals Ltd

Shanghai Roche Pharmaceuticals Ltd , founded in 1994 with a total investment of USD 45 million, is dedicated to the fields of oncology, virology and transplantation etc., aiming at improving patients' quality of life. Following the founding of Roche R&D Center China Ltd in 2004 and Pharma Development Center in China in 2007, Roche established a complete medical value chain that covers Research, Development, Production, Sales & Marketing. In 2008, with the launch of the Roche Shanghai Expansion Project and the foundation of its Pharma Partnering Asia Office in Shanghai, Roche further proved its long-term commitment to China. On September 1, 2009 the APAC regional office of Rochemoved to Shanghai and "Roche Pharma Development Center in China" was upgraded to "Roche Pharma Development Centerin Asia Pacific" as well. Meanwhile, as a responsible corporate citizen, SRPL has been actively co-operating with the government and is dedicated to all kinds of CSR undertakings such as: support to disaster-struck areas, education programs as well as environmental protection.